Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International's Work In Process history runs 3 years deep, the most recent figure standing at $18.3 million for Q4 2023.

• Quarterly Work In Process rose 189.26% year-over-year to $18.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $18.3 million (up 189.26% YoY) and the FY2023 annual result came in at $18.3 million, up 189.26% from the prior year.
• Work In Process was $18.3 million for Q4 2023 at Kiniksa Pharmaceuticals International, up from $13.4 million in the prior quarter.
• Across five years, Work In Process topped out at $18.3 million in Q4 2023 and bottomed at $148000.0 in Q1 2022.
• A 3-year average of $8.3 million and a median of $6.5 million in 2022 frame the typical range for Work In Process.
• Peak annual rise in Work In Process reached 9033.11% in 2023, while the deepest fall reached 189.26% in 2023.
• Kiniksa Pharmaceuticals International's Work In Process stood at $4.2 million in 2021, then surged by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
• Business Quant data shows KNSA's Work In Process at $18.3 million in Q4 2023, $13.4 million in Q3 2023, and $6.6 million in Q2 2023.